Arriello
Arriello is a privately held, Dublin-headquartered B2B professional services firm delivering pharmacovigilance, regulatory affairs, and quality compliance services to pharmaceutical companies, biotech firms, and Marketing Authorization Holders across 150+ countries via 128+ partner vendors.
- Company typePrivate
- Founded2008
- HeadquartersSandyford, Ireland
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Arriello does
Arriello is a privately held, Dublin-headquartered B2B professional services firm founded in 2008 that delivers pharmacovigilance, regulatory affairs, and quality and compliance services to pharmaceutical companies, biotech firms, and Marketing Authorization Holders. The company operates across five offices (Dublin HQ, Boston, San Francisco, Lisbon, Prague) and coordinates a network of 128+ partner vendors to deliver Local Affiliate Services in 150+ countries, covering in-country pharmacovigilance, regulatory representation, and quality support. Its client base spans enterprise pharma (ICON plc, Sintetica, Cinfa, Bracco, Aspen, Bluefish) and smaller biotechs, with service engagements structured as project-based and multi-year contracts priced via RFI/RFP.
The company's service portfolio is organized around three core pillars — Pharmacovigilance, Regulatory Affairs, and Quality & Compliance — and includes a wide range of capabilities: QPPV and LPPV services, EudraVigilance management, ICSR case processing, signal detection, aggregate reports, orphan drug designation, paediatric investigation plans, SME applications, marketing authorization applications, dossier publishing, linguistic review, artwork and labeling, GxP auditing, and mock regulatory inspections. Its underlying technology stack is built on the Veeva Vault Safety database, a cloud-based, CFR 21 Part 11 compliant platform providing automated coding, duplicate checking, case tracking, and direct gateway submissions to EMA, FDA, and MHRA under ICH E2B (R3) standards. The firm holds ISO 9001 and ISO 27001 certifications (TÜV-audited) and was named Pharma Contract Services Company of the Year at the 2025 Pharma Industry Awards.
Arriello's go-to-market is sales-led and consultative, targeting enterprise pharma and biotech clients through direct outreach, RFI/RFP submissions, industry events, and content marketing (blog, white papers, webinars, case studies). Revenue is generated through professional services fees tied to project scope and duration, with multi-year contract structures that embed the firm into clients' regulatory and safety workflows. The company is privately held with no disclosed external investors, funding rounds, or parent company, and operates independently through its Irish legal entity, Arriello Ireland Ltd., and regional offices.
Arriello firmographics
Firmographics- Name
- Arriello
- Legal name
- Arriello Ireland Ltd.
- Website
- https://arriello.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Arriello is a privately held, Dublin-headquartered B2B professional services firm delivering pharmacovigilance, regulatory affairs, and quality compliance services to pharmaceutical companies, biotech firms, and Marketing Authorization Holders across 150+ countries via 128+ partner vendors.
- Ownership category
- akta.pro rank
Arriello industry classification
Industry- Product category
- Pharmaceutical Regulatory & Pharmacovigilance Services
- NAICS
- Other Management Consulting Services (541618)
- SIC
- Services-Management Consulting Services (8742)
- akta.pro primary industry
- Pharmacovigilance Quality & Compliance (PV audits, QPPV support, PSMF) (HLAGAKAH)
- akta.pro secondary industry
- Pharmacovigilance, Drug Safety & Risk Management FSP (HLAGAOAF)
Keywords
Where Arriello is headquartered
LocationHeadquarters
- HQ city
- Sandyford
- HQ country
- Ireland
- HQ region
- Europe
Offices5 records
Markets served
Arriello business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Professional Consulting Services: Project-based consulting engagements for pharmacovigilance, regulatory affairs, and quality compliance services. Services are delivered through dedicated project teams with expertise across clinical safety, regulatory submissions, and compliance auditing. Revenue is generated through service fees tied to project scope and duration.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based custom pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
Arriello product offering
Product offeringCore offering
Arriello provides professional consulting and outsourcing services spanning pharmacovigilance, regulatory affairs, and quality & compliance across the full pharmaceutical product lifecycle. Core deliverables include EU-QPPV/LPPV services, ICSR case management, signal and benefit-risk management, drug safety database hosting (Veeva Vault Safety), regulatory strategy and dossier development, marketing authorization applications, GxP auditing, and inspection readiness support delivered through dedicated project teams.
Product overview
Arriello is a pharmacovigilance, regulatory affairs, and quality & compliance services company offering integrated consulting and outsourcing solutions throughout the pharmaceutical product lifecycle. The company operates across three core service areas: Pharmacovigilance Services (including QPPV, EudraVigilance, ICSR Case Management, Signal Detection, Benefit-Risk Management, and a Veeva Vault Drug Safety Database), Regulatory Affairs Services (covering regulatory strategy, dossier development, clinical trial regulatory, marketing authorization applications, lifecycle management, and CMC/medical writing), and Quality & Compliance Services (including GxP auditing, quality management systems, and commercialization readiness). Additional offerings include Clinical Safety Services, Medical Information & PV Integration, Literature Monitoring, Case Migration Services, and Local Affiliate Services across 150+ countries. The portfolio also includes specialized services for scientific advice, paediatric investigation plans, orphan drug designation, SME applications, regulatory due diligence, artwork/labeling, translations, and readability testing.
Differentiator
Problem solved
Functional benefit
Companies that use Arriello
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles4 records
Arriello technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Arriello partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights6 records
Arriello competitors and assessment
Company assessmentOthers
- Veeva Systems: Provider of the Veeva Vault Safety database that Arriello leverages as its core safety platform; not a direct competitor but rather enabling technology vendor closely tied to Arriello's service delivery model.
Direct peers
- PHASTAR: Statistical and pharmacovigilance services CRO providing PV/regulatory support to pharma/biotech, with similar mid-size international footprint and clinical safety overlap.
- PrimeVigilance: Premier global pharmacovigilance and regulatory services provider; now part of Thermo Fisher/PPD. Directly competes with Arriello on PV services, QPPV offerings, and regulatory consulting to pharma/biotech sponsors.
- PharSafer: UK-headquartered pharmacovigilance and drug safety specialist offering QPPV, signal detection, and safety database services; a close direct competitor in the mid-market PV outsourcing segment.
- APCER Life Sciences: Specialized pharmacovigilance, regulatory affairs, and medical writing services firm for pharma/biotech; directly overlaps with Arriello across QPPV, ICSR processing, and regulatory consulting deliverables.
- Ergomed (now Ergomed Group / acquired by Permira): CRO with dedicated pharmacovigilance and regulatory services line; competes with Arriello on full-service drug safety and regulatory affairs outsourcing for mid-pharma and biotech.
Broad incumbents
- ICON plc: Major global CRO with extensive PV, regulatory affairs, and clinical safety services; directly competes with Arriello for enterprise pharma clients and is itself a named Arriello customer for project collaboration.
- Parexel International: Large global CRO with dedicated pharmacovigilance, regulatory consulting, and quality assurance lines; competes in the broader pharma services market where Arriello also operates.
- IQVIA: Global clinical and commercial CRO offering comprehensive pharmacovigilance, regulatory affairs, and quality compliance services as part of a much broader portfolio; competes at the larger enterprise end of Arriello's market.
Emerging players
- Clinipace Worldwide: Mid-size CRO with PV and regulatory services for emerging/specialty pharma; partial overlap with Arriello around regulatory affairs and safety services for smaller sponsor clients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Arriello social profiles
Digital presenceArriello compliance and trust
Trust signalCompliance2 records
Arriello financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arriello leadership team
Management profileNumber of profiles
Profiles1 record
Arriello funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arriello M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arriello
What does Arriello do?
Arriello provides professional consulting and outsourcing services spanning pharmacovigilance, regulatory affairs, and quality & compliance across the full pharmaceutical product lifecycle. Core deliverables include EU-QPPV/LPPV services, ICSR case management, signal and benefit-risk management, drug safety database hosting (Veeva Vault Safety), regulatory strategy and dossier development, marketing authorization applications, GxP auditing, and inspection readiness support delivered through dedicated project teams.
Is Arriello a public or private company?
Arriello is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Arriello founded?
Arriello was founded in 2008. It employs 101 to 250 people.
Where is Arriello based?
Arriello is headquartered in Sandyford, Ireland, in the Europe region.
How does Arriello make money?
One revenue line is on record: professional Consulting Services.
Who are Arriello's main competitors?
Veeva Systems is listed as an others. Direct peers are PHASTAR, PrimeVigilance, PharSafer, APCER Life Sciences and Ergomed (now Ergomed Group / acquired by Permira). Broad incumbents are ICON plc, Parexel International and IQVIA. Clinipace Worldwide is listed as an emerging player.
Does Arriello have an API?
No public API is recorded for Arriello.
What industry is Arriello in?
Arriello's product category is Pharmaceutical Regulatory & Pharmacovigilance Services. Its primary akta.pro industry code is HLAGAKAH, Pharmacovigilance Quality & Compliance (PV audits, QPPV support, PSMF), with a secondary code of HLAGAOAF, Pharmacovigilance, Drug Safety & Risk Management FSP. Its NAICS code is 541618 and its SIC code is 8742.